SEC Comment Letter for Akari Therapeutics Plc (AKTX) (CIK 0001541157) (AKTX) — Aug 24, 2017
Akari Therapeutics Plc (AKTX) (CIK 0001541157)
Date: Aug. 24, 2017 · CIK: 0001541157 · Accession: 0000000000-17-030010
AI Filing Summary & Sentiment
Reasoning
Letter
August 24, 2017 Ray Prudo Interim Chief Executive Officer Akari Therapeutics, Plc 75/76 Wimpole Street London W1G 9RT United Kingdom Akari Therapeutics, Plc Registration Statement on Form F-3 Filed August 18, 2017 File No. 333-220052Re: Dear Dr. Prudo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at (202) 551-3798 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Gary Emmanuel, Esq.
Show Raw Text
August 24, 2017 Ray Prudo Interim Chief Executive Officer Akari Therapeutics, Plc 75/76 Wimpole Street London W1G 9RT United Kingdom Akari Therapeutics, Plc Registration Statement on Form F-3 Filed August 18, 2017 File No. 333-220052Re: Dear Dr. Prudo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at (202) 551-3798 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Gary Emmanuel, Esq.